Betifisolimab (Synonyms: MSB-2311)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Betifisolimab  (Synonyms: MSB-2311)

Betifisolimab (MSB-2311) 是一种针对免疫抑制配体 PD-L1 的人源化单克隆抗体。Betifisolimab 具有用于晚期实体瘤和血液恶性肿瘤研究的潜力。

  • Betifisolimab (Synonyms: MSB-2311)
  • Betifisolimab (Synonyms: MSB-2311)

  1. Betifisolimab (Synonyms: MSB-2311)
  2. Betifisolimab (Synonyms: MSB-2311)

CAS No. : 2460539-60-8

规格 是否有货
1 mg 询价
5 mg 询价

* Please select Quantity before adding items.

Betifisolimab 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research[1].

同型

Human IgG1 kappa
推荐同型对照抗体

Human IgG1 kappa, Isotype Control
种属

Chimeric
体外研究
(In Vitro)

Betifisolimab (MSB-2311) 是一种人源化 PD-L1 抗体，具有独特的 pH 依赖性抗原结合特性，可实现肿瘤内循环并增强肿瘤渗透[1]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Betifisolimab 相关抗体:
Clinical Trial

CAS 号

2460539-60-8
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Betifisolimab (Synonyms: MSB-2311)
    Human IgG1 kappa
纯度 & 产品资料
Data Sheet (517 KB) 抗体抑制剂使用指南 (1152 KB)

参考文献

  • [1]. Xichun Hu, et al. MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients. Journal of Clinical Oncology 38, no. 15_suppl.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务